Other therapy.
Durvalumab + olaparib + paclitaxel in High-risk HER2-negative ESBC: I-SPY2 trial results
I-SPY2 Trial, Cancer Cell 39, 989–998, 2021 Authors: Pusztai et al.
Read MoreOther therapy.
I-SPY2 Trial, Cancer Cell 39, 989–998, 2021 Authors: Pusztai et al.
Read MorePUBLICATION: ASCO 2021 Authors Nina D’Abreo1,2, Abhinav Rohatgi1,2, Douglas Read More
Publication: St. Gallen Authors: Jennifer A. Crozier, Lisa Blumencranz, Read More
Publication: St Gallen Authors: M. Kleijn, J. McKelley, Read More
Publication: Miami Breast Authors: Pat Whitworth, Jennifer A. Crozier, Robert Read More
PUBLICATION: SABCS 2020 AUTHORS: Dipali Sharma, Lisa E. Blumencranz, Read More
PUBLICATION: SABCS 2020 AUTHORS: Margaret Chen, Ava Kwong, Carolyn Hendricks, Read More
PUBLICATION: SABCS 2020 AUTHORS: Joseph McKelley, Jennifer Wei, Brian Hoxeng, Read More
PUBLICATION: SABCS 2020 AUTHORS: Beth-Ann Lesnikoski, Jennifer A. Crozier, Gordan Read More
PUBLICATION: SABCS 2020 AUTHORS: Jennifer A. Crozier, Julie Barone, Kalyan Read More